Excalipoint Raises $68.7M for T Cell Engager Development

Deal Summary

Shanghai-based biotech Excalipoint announced it has raised $68.7 million to advance its T cell engager platform. The funding will support the development of next‑generation immunotherapies. Investors were not disclosed.